Close

Welcome back to Stockhouse
Member Sign In

Email or Username:
Password:
Close

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History  |  Analysts  |  Earnings  |  Insiders

AEterna Zentaris Inc T.AEZ

Sector: Healthcare | Sub-Sector: Biotechnology
Alternate Symbol(s):  AEZS

AEterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing novel treatments in oncology and endocrinology.
Price: $0.66 Volume: 44,774
Change: $0.00 % Change: 0.00%
Day High/Low: N/A/N/A 52 Week High/Low: 1.68/0.55
Last Traded: January 29, 2015 10:57 Transaction Volume: 500
Open: Previous Close: 0.66
Bid: 0.63 Ask: 0.71
Bid Size: 19500 Ask Size: 7000
Market Cap: 43.2m Shares Out: 65.5m
PE Ratio: N/A Dividend Yield: N/A

Latest Bullboard Posts

  • RE:RE:RE:RE:Resume trading

    0 stars

    they might do another reverse split to keep their naz listing...their horn of aplenty...never ending funding up to now has always been...

    4.5 stars


  • RE:RE:RE:RE:Resume trading

    0 stars

    The biggest risk is how will Ascend respond to the FDA rejection. They were suppose to co-promote both drugs. Lawsuit won't help either...

    2.5 stars


  • RE:RE:RE:Resume trading

    0 stars

    I'm gonna hold....lots of risk though, they've got a nice pipeline but the FDA ruling doesn't help investor confidence for their other...

    2 stars


  • RE:RE:Resume trading

    0 stars

    That press release was from 2011...obviously a lot has happened since. Still mangement should not have been blindsided by the ruling

    2.5 stars


  • RE:Resume trading

    0 stars

    They were not concerns......................it was a total rejection of the clinical results. We were told that Phase 3 endpoints were...

    2.5 stars